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Controlled drug delivery from composites of 
nanostructured porous silicon and poly(l-lactide)
The therapeutic effects of existing, common 
drugs can be enhanced via the use of controlled 
drug delivery systems. Hence, the develop-
ment of new delivery systems is often consid-
ered as a commercially viable alternative to the 
expense of drug discovery and development [1–3]. 
Controlled drug delivery systems have now been 
developed to the point where they can facilitate 
site-specific delivery at precisely controlled rates 
[4–9]. Control over the delivery rate minimizes 
the toxicity and side effects of the drug being 
delivered [1,10–15]. In order for a drug delivery 
system to provide a therapeutic payload with the 
maximum therapeutic benefit, the release profile 
of new drug delivery systems typically need to be 
carefully adapted to the particular application.
Our current research goal is to develop new 
vehicles for localized transfer of drugs to the 
anterior segment of human eyes affected by the 
sequelae of ocular inflammation. For example, 
uveitis, defined as inflammation of the uveal 
tract, has an estimated prevalence of 17 per 
100,000 population and is responsible for 10% 
of all cases of serious visual loss in developed 
countries [16]. These conditions are typically 
treated with topical and oral glucocortico-
steroids. In spite of these drugs being associated 
with significant side effects and often insuffi-
ciently control acute or recurrent inflammation, 
they remain the mainstay of current treatment. 
Additional systemic immunosuppression with 
agents such as methotrexate or cyclophos-
phamide may then be required [17]. However, 
these drugs must be administered daily and 
their side effects, although manageable, are not 
trivial [18]. Another targeted disease, primary 
open-angle glaucoma, has a prevalence of 1–4% 
in different populations and is the second most 
common cause of blindness in the developed 
world [19]. Treatment consists of reducing intra-
ocular pressure with drugs or surgery designed 
to increase outflow of aqueous humor from 
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the eye [20,21]. To reduce fibrosis after surgery, 
cytotoxins may be applied to the eye repeat-
edly, but this procedure can cause damage to 
the  extraocular tissues.
A biomaterial that can support localized and 
sustained drug delivery to the cornea and ante-
rior segment of the eye may prove a safe and 
effective method of delivery and improve exist-
ing therapeutic options in patients affected by 
acute anterior uveitis or glaucoma. Similar con-
siderations apply to conditions, such as corneal 
neovascularization, that follow the inflamma-
tion caused by trauma or infectious keratitis, or 
that may accompany ocular surface disease [22]. 
Local delivery of an antiangiogenic agent loaded 
into a biodegradable material might well be a 
viable therapeutic option.
Silicon (Si)-based materials, including 
silicones, silica, porous Si (pSi) and micro-
machined crystalline Si are commonly used in 
drug delivery because they are relatively bio-
inert [23,24]. Fabricating pSi films from single 
crystalline Si is achieved by an electrochemical 
etch in electrolyte mixtures of aqueous hydro-
f luoric acid (HF) and ethanol. Changes to 
wafer resistivity and process parameters such as 
electrolyte concentrations and current densities 
allow for the generation of a wide range of pore 
sizes and structures [25]. pSi has key advantages 
because, unlike flat Si, it degrades completely in 
aqueous solutions into nontoxic silicic acid [25], 
the major form of Si in the environment and 
human body [24], and is proving to be remark-
ably inert and noninflammatory within the 
body [26]. The material has a very high surface 
area (400–800 m2/g) [25], a property essential 
for high drug loading regimes. Since the mate-
rial is insoluble in organic solvents, loading 
of a wide range of small-molecule drugs with 
different solubilities is possible. Also, in con-
trast to most polymeric materials, the surface 
chemistry of pSi can be modified by simple one-
step chemical treatments without affecting its 
material properties. Surface modification allows 
tuning of the loading and release characteristics 
of a wide range of bioactives [27–30]. Depending 
on the chemical doping of the Si material base, 
etching conditions and surface modification 
[31–33], the degradation kinetics can be controlled 
from hours to months. Finally, recent reports 
have shown that the photonic properties of pSi 
allow self-reporting of drug loading and release 
[7,34]. An additional benefit associated with the 
use of pSi is that it can be processed into films 
supported on Si, free-standing membranes and 
micro- or nano-particles [32,34–38].
Polymeric drug delivery devices and systems 
have proved invaluable in enhancing the thera-
peutic efficacy of drugs, while reducing toxicity 
and enhancing patient compliance [39]. One pop-
ular biodegradable polymer class for drug deliv-
ery is the polyesters, which include polylactides, 
poly(e-caprolactone), poly(3-hydroxybutyrate 
and poly(glycolic acid) [40]. These polymers and 
various copolymer compositions have shown 
considerable potential as effective drug carri-
ers [41,42] and have been extensively studied for 
the controlled release of drugs due to their tun-
able degradation rates (from months to years), 
wide range of mechanical properties and biode-
gradability [40,43–49]. Poly(l-lactide) (PLLA) is 
particularly advantageous since its degradation 
product, lactic acid, is well tolerated by the body 
[50–53]. The degradation properties of polyesters 
have been widely studied [54,55] and are known to 
be affected by polymer properties (i.e., molecular 
weight, chemistry, wettability and crystallinity) 
and also the properties of the release medium 
(i.e., pH, ionic strength and solvent) [56]. 
We have previously demonstrated that com-
posite membranes of pSi and poly(e-caprolac-
tone) can be implanted successfully into the 
subconjunctival space of the rat eye, without 
obscuring the visual axis [37,57]. These materi-
als did not erode the under- or overlying tissue, 
did not cause any significant accumulation of 
acute inflammatory cells around the insert, did 
not become vascularized and remained visible 
with the operating microscope for periods over 
8 weeks. Eventually, the membranes dissolved 
without a trace, leaving behind a small, encap-
sulated space. Human lens epithelial cells and 
primary human corneal explants adhered to the 
membranes, where they remained viable and 
underwent division. 
Here, we investigated the properties of com-
posite materials of pSi and PLLA as advanced 
materials for controlled drug release, combining 
the useful drug release properties of pSi with the 
good processability of PLLA. In particular, we 
prepared three different formats of composites 
(Figure 1) using surface-initiated polymerization 
to graft PLLA to pSi (pSi–PLLA; grafted), spin-
coating of bulk polymerized PLLA onto pSi films 
(pSi–PLLA; spin-coated) and pSi–PLLA mono-
liths prepared by mixing of pSi microparticles 
into a molten PLLA matrix. Based on our previ-
ous work, we speculate that the resulting films 
and monoliths can be implanted into the sub-
conjunctival space. Others have demonstrated 
that pSi particles can be injected into the vitreous 
for drug delivery to the posterior chamber of the 
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eye [57]. We examined the composite materials’ 
ability to release a model drug, the cytotoxic 
topoisomerase inhibitor camptothecin (CPT), 
and investigated cytotoxicity in vitro and deter-
mined that all three composite formats show 
release behavior that is compatible with localized 
drug delivery to the ocular surface. 
Materials & methods
 n Chemicals
Dichloromethane (CH
2
Cl
2
, Merck, NJ, USA) 
and toluene (Aldrich, MO, USA) were distilled 
over calcium hydride and stored over molecular 
sieves away from light. Tetrahydrofuran (THF) 
was distilled over sodium and benzophenone 
and stored over molecular sieves away from light. 
l-lactide ([3S]-cis-3,6-dimethyl-1,4-dioxane-2,5-
dione; 98%, Aldrich) was recrystallized before 
use. Polyethylene glycol (PEG) 6000 (average 
molecular weight 6000–7000 g/mol, 130–170 
repeats with hydroxyl terminal functionality), 
HF 48% (BDH/Merck, Darmstadt, Germany) 
and tin(II) 2-ethylhexanoate (Sn(Oct)
2
i; 95%, 
Aldrich) were used as received. (S)-(+)-CPT 
(CPT, Aldrich, 95%) was stored at 2–4°C and 
protected from light at all times. Methanol 
(Merck, analytical grade, 99.5%), acetone (Ajax, 
NSW, Australia, analytical grade, 99.5%) and 
ethanol (Ajax, absolute, 100%) were used for 
etching and washing without further puri-
f ication. N,N-dimethylformamide (DMF) 
was purified via standard laboratory proto-
cols including drying over magnesium sulfate 
followed by distillation at reduced pressure [58]. 
MilliQ® water 18.2 MW was obtained from 
a Labconco (MO, USA), Water Pro PS water 
purifier. Phosphate-buffered saline (PBS), pH 
7.4, was prepared in MilliQ water from sodium 
chloride (analytical grade, Chemsupply, Port 
Adelaide, Australia, 99.0%; 136.9 mM), potas-
sium chloride (analytical grade, Biolab Scientific, 
Auckland, New Zealand, 99.5%; 2.68 mM), di-
sodium phosphate di-hydrate (AR, Chemsupply, 
99.0%; 3.71 mM) and potassium dihydrogen 
orthophosphate (analytical grade, Ajax, 99.0%; 
1.76 mM). The pH was adjusted by buffering 
with 1 M solutions of sodium hydroxide (Ajax, 
analytical grade) or hydrochloric acid (Aldrich, 
reagent grade) in MilliQ water.
 n Production & loading of pSi–PLLA 
(grafted) composite materials
Production of pSi films
For infrared (IR) studies, p+ type Si wafers 
(Silicon Quest International, NV, USA; boron 
doped, 381 ± 25 µm, resistivity of 3–6 Wcm, 
<1–0–0>) were etched in 1:1 HF:ethanol elec-
trolyte at a current density of 36.67 mA/cm2 
using a etching cell with an exposed area of 
1.8 cm2. The pSi films were then washed with 
copious amounts of methanol, ethanol, acetone 
and finally CH
2
Cl
2
 and dried in a stream of N
2
. 
Ozone oxidation was performed using a Fischer® 
OZON, Ozon-Generator 500 (Fischer America, 
São Paolo, Brazil). All oxidations were performed 
at an ozone rate of 3.25 g/h. 
pSi
Surface-initiated ring
opening polymerization
of PLLA
Electropolishing and
sonication
Drug
loading pSi microparticles
Drug loading
Drug loading solution
Casting of pSi
into PLLA melts
pSi–PLLA monolithspSi–PLLA (grafted)
Drug loading
pSi–PLLA (spin-coated)
PLLA spin-coating
pSi microparticles
Figure 1. Drug loading of porous silicon films and microparticles, and generation of porous 
silicon and poly(l‑lactide) composite materials.
PLLA: Poly(l-lactide); pSi: Porous silicon.
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Surface silanizations 
N-(hydroxyethyl)-3-aminopropyl trimethoxy-
silane (HEAPS) and N-(triethoxysilylpropyl)-
O-polyethylene oxide urethane (PEGS) were 
purchased from Gelest Inc. (VA, USA), and used 
as received. Surface treatments with HEAPS 
and PEGS silanes were carried out on oxidized 
pSi (pSi-Ox) surfaces at room temperature for 
10 min by submersion in an anhydrous solution 
of silane in toluene (50 mM). Afterwards, the 
surfaces were rinsed with toluene, acetone and 
CH
2
Cl
2
 and dried under a stream of N
2
.
Ring-opening graft polymerization 
of PLLA 
Oxidized and silanized pSi films were soaked 
in 10 ml of toluene containing 5 µmol Sn(Oct)
2
 
catalyst for 1 h at 50°C before addition of 
10 mmol (1.44 g) of recrystallized l-lactide. The 
polymerization reaction proceeded for 72 h at 
110°C. Upon completion of the polymerization, 
the pSi films were removed and washed with tol-
uene, acetone and CH
2
Cl
2
 before being treated 
by Soxhlet extraction in anhydrous toluene for 
30 min. All pretreatments, polymerizations and 
washing procedures were carried out under an 
N
2
 atmosphere.
CPT loading of PLLA-grafted pSi films
PLLA-grafted pSi films (1.8 cm2) were placed 
into 10 ml of a solution of 2.5 mg/ml CPT 
(Aldrich, 95%) in dry distilled DMF for 2 h 
before being removed and dried under vacuum 
(10 mm/Hg) in a desiccator. 
 n Production & loading of pSi–PLLA 
(spin-coated) composite materials
Bulk polymerization of PLLA 
A total of 5 g of recrystallized l-lactide was 
heated above its melting point (~140°C) and 
1 wt% of Sn(Oct)
2
 catalyst was added to the 
melt and stirred for 4 h to allow for polymeriza-
tion. Upon completion of the polymerization, 
the polymer block was put through a Soxhlet 
extraction for 2 h with toluene to remove any 
remaining catalyst. The cooled solid block 
of PLLA was manually pulverized into a fine 
white powder.
Spin coating of PLLA 
pSi-Ox films (1.8 cm2) were loaded as described 
under the section ‘CPT loading of PLLA grafted 
pSi films’, but a higher concentration of CPT 
(10 mg/ml) was used in order to compensate for 
the removal of CPT by THF during the spin 
coating process. Spin coating was performed 
using a WS-400B-6NPP/LITE model spin 
coater (Laurell Technologies Corporation, PA, 
USA) at 5000 rpm with a solution of 0.22 mg/ml 
PLLA in THF at 80°C on CPT-loaded pSi films. 
Once dried, the surfaces were removed from the 
spin coater and placed on a hotplate at 200°C 
for 10 s to further assist the infiltration of the 
molten PLLA into the pores.
 n Production & loading of PLLA 
monolith composite materials
Fabrication of pSi microparticles
Microparticles were fabricated from p++ Si 
wafers (boron doped, resistivity <0.001 W cm, 
<1–0–0>) supplied by Virginia Semiconductors 
(VA, USA) using a custom-built, 18-cm2 tef-
lon etching cell. The wafer was anodized in 
3:1 HF:ethanol solution with a density of 
111 mA/cm2 for 4 min and then electro polished 
for 30 s at 500 mA/cm2. CH
2
Cl
2
 was then 
added, and the free-standing porous layer was 
manually fractured into microparticles for col-
lection. The pSi microparticle suspension was 
sonicated for 20 min (to reduce the particle size) 
before being filtered and washed with ethanol 
and CH
2
Cl
2
. Ozone oxidation was performed 
as described above after an overnight incubation 
in an 80°C oven.
Production & loading of pSi–PLLA 
monoliths 
Monoliths were produced by placing bulk 
polymerized PLLA into a casting plate, consist-
ing of circular holes (3 mm in depth and 3 mm 
in diameter) and heating the material to just 
above the melting point of the PLLA (~170°C, 
for 10 s). The material was then slowly cooled 
to room temperature (over 5–10 min) before 
the monoliths were removed from the mould. 
To facilitate easy removal of the monoliths, 5% 
w/w of PEG 6000 was added as a plasticizer dur-
ing the melt casting. Three different monolith 
formulations were produced:
  PLLA only: PLLA and PEG plasticizer 
(95:5 w/w); 
  PLLA–CPT: 0.2 mg of CPT per 50 mg of 
PLLA:PEG (95:5 w/w); 
  pSi–PLLA–CPT: the pSi microparticles pre-
loaded with approximately 1 mg of CPT per 
50 mg of pSi (prepared as described below) 
were subsequently mixed into 250 mg of 
PLLA:PEG (95:5) to give a final loading of 
0.2 mg of CPT per 50 mg of PLLA:PEG 
(95:5 w/w).
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As each monolith weighed approximately 
76.5 ± 0.3 mg, the average loading of each 
monolith was approximately 0.31 mg or 
878.4 ± 3.9 nmol of CPT.
The CPT-loaded pSi microparticles were 
prepared by adding 500 µl of 2.5 mg/ml CPT 
solution (in dry distilled DMF) to an Eppendorf 
tube containing approximately 50 mg pSi. After 
2 h, the excess CPT solution was removed from 
the Eppendorf tubes and the microparticles were 
completely dried in a desiccator under vacuum 
conditions (0.5 mm/Hg). The final loading of 
microparticles was calculated gravimetrically as 
2.87 µmol of CPT per 50 mg of pSi (or 1 mg 
CPT per 50 mg pSi). These particles were then 
loaded into PLLA monoliths (as described above 
for pSi–PLLA–CPT monoliths).
The pSi–PLLA nomenclature was chosen 
for the monolith composites (cf. the pSi–PLLA 
[grafted] and pSi–PLLA [spin-coated]) since 
PLLA is the major component of these materials, 
rather than pSi.
This fabrication incorporates high-temper-
ature processing. However, we expect there to 
be little damage to the CPT as the maximum 
temperature of 170°C is only applied for a short 
time period (~10–20 s) and is well below the 
260°C decomposition point of CPT [59,60]. 
 n Analysis techniques
Interferometric reflectance spectroscopy
Interferometric reflectance spectroscopy mea-
surements were performed to determine the 
porosity of the pSi films. Briefly, reflectivity 
data were recorded for wavelengths between 
400 and 1000 nm, with an acquisition time 
of 100 ms on a USB2000 spectro photometer 
(Ocean Optics, FL, USA). To obtain the effec-
tive optical thickness of the pSi films, a fast 
Fourier transform was applied using the IGOR 
program (Wavemetrics, OR, USA). The effec-
tive optical thickness obtained with the dry films 
and the film filled with ethanol were modeled 
with a two-component Bruggeman effective 
medium model. This allowed for the porosity 
of the films to be calculated. The refractive indi-
ces for air, ethanol and pSi used in the model 
are 1.00, 1.36 and 2.05, respectively. Separate 
gravimetric measurements were performed on 
all samples to determine porosity and thickness.
Size exclusion chromatography
Size exclusion chromatography was performed 
on a system comprising a 2690-separation 
module (Waters, MA, USA) equipped with a 
Styragel® HR4E column (300 × 4.6 mm; Waters) 
providing an effective molecular weight range 
of 50–100,000 g/mol. A 410-refractive index 
detector (Waters) and a 996-photodiode array 
detector (Waters) were coupled in series. The 
eluent was THF with a flow rate of 0.3 ml/min. 
Number- and weight-average molecular weights 
were evaluated using Waters Millennium soft-
ware and polystyrene standards. A polynomial 
was used to fit the log M versus time calibration 
curve, which was linear across the molecular 
weight range.
Thermal gravimetric analysis
Thermal gravimetric analysis (TGA) experi-
ments were conducted under N
2
 conditions at 
a flow rate of 50 ml/min on a SDT 2960 (TA 
Instruments, DE, USA). The temperature was 
ramped from room temperature to 550°C at 
10°C/min. Each sample was accurately weighed 
by the TGA before measurements were per-
formed, and all samples’ weights ranged from 
10 to 11 mg for consistency.
Water contact angle
Water contact angles (WCAs) were measured by 
placing a 1-µl drop of water on the sample sur-
face and capturing a digital image using a Super 
Dynamic wv-BP550 Closed Circuit TV camera 
(Panasonic, NSW, Australia). The contact angle 
measurements were analyzed by Scion Image 
for Windows frame grabber software (beta ver-
sion 4.0.2). Three replicate measurements were 
performed for each sample.
IR spectroscopy 
All IR spectra were obtained using a 
Nicolet Avatar 370MCT (Thermo Electron 
Corporation, MA, USA) equipped with a stan-
dard trans mission accessory. Spectra of the 
pSi films were recorded and analyzed using 
OMNIC™ Version 7.0 software (Thermo 
Electron Corporation), in the range of 650–
4000 cm-1 at a resolution of 4 cm-1. A back-
ground spectrum was taken on an unetched 
Si wafer.
Scanning electron microscopy
Scanning electron microscopy (SEM) was per-
formed on either a XL30 field emission SEM 
(acceleration voltage of 10 kV; Philips, Holland) 
or a Phenom benchtop SEM (acceleration volt-
age of 2 kV; FEI, OR, USA). To help facilitate 
the dissipation of charge build-up, all samples 
(except the microparticles) were coated with a 
5-nm thick layer of Pt before analysis, according 
to our standard laboratory protocol [37].
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Atomic force microscopy
Tapping mode atomic force microscopy (AFM) 
was performed on a Multimode Nanoscope with 
a Nanoscope IV controller (Veeco Corporation, 
CA, USA). Commercial Si cantilevers (FESP) 
acquired from Veeco Corporation with the fol-
lowing specifications were used for all experi-
ments: beam shaped, 225 µm length, 28 µm 
width, 3 µm thickness, 2.8 N/m force constant, 
75 kHz resonance frequency and a tip height and 
radius of 10–15 µm and <8 nm, respectively. All 
AFM was performed at ambient conditions and 
the images were processed and analyzed using the 
Nanoscope 5.31r1 software (Veeco Corporation).
CPT release assay by fluorimetry
The ability of the composite materials to release 
their CPT payload into 3 ml of static (unstirred) 
solution of PBS (pH 7.4) at 37°C was analyzed 
using a time-drive program and a standard 
quartz cuvette to collect f luorescence data. 
Fluorimetry was performed on a LS55 lumines-
cence spectrometer (Perkin Elmer Instruments, 
MA, USA) with an excitation wavelength of 
Time (h)
0 2 4 6 8 10 12 14 16
0
5
10
15
20
25
30
35
40
45
50
CP
T 
re
le
as
ed
 (n
mo
l/c
m2
)
pSi-Ox
pSi-Ox–PLLA
pSi–HEAPS–PLLA
pSi–PEGS–PLLA
pSi-Ox
pSi-Ox–PLLA
pSi–HEAPS–PLLA
pSi–PEGS–PLLA
0 0.5 1 1.5 2 2.5 3 3.5 4
0
20
40
60
80
100
120
Time0.5 (h0.5)
CP
T 
re
le
as
ed
 (%
)
Figure 2. Drug release from porous silicon–poly(l‑lactide; grafted) surfaces. (A) Release 
curves of CPT from grafted pSi–PLLA composite materials and (B) corresponding Higuchi plot of 
CPT release. 
CPT: Camptothecin; HEAPS: N-(hydroxyethyl)-3-aminopropyl trimethoxysilane; Ox: Oxidized; 
PEGS: N-(triethoxysilylpropyl)-O-polyethylene oxide urethane; PLLA: Poly(l-lactide); 
pSi: Porous silicon.
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340 nm and emission wavelength of 434 nm, 
the slit width was 3 nm and the photomulti-
plier voltage was 775 V. The release cuvettes 
were sealed with Teflon® (DuPont Co., DE, 
USA) stoppers to prevent evaporation during 
the release period. Release rates were calculated 
from the slope of release curves obtained. The 
CPT-loaded pSi films were cut into smaller chips 
(chip areas varied between 0.1 and 0.2 cm2) and 
the actual amount of CPT released was calcu-
lated via the use of a calibration curve and nor-
malized relative to the chip area (not the pSi 
surface area) to determine the amount of CPT 
released per cm2 of pSi chip. This procedure 
enabled easy comparison of the release data. A 
minimum of two release curves were averaged to 
give the curves shown in Figures 2–4. Despite the 
very low solubility of CPT in aqueous solutions 
(14.2 ± 2.9 µM) [61], sink conditions were main-
tained for all release experiments by ensuring 
that the maximum release concentrations were 
less then 1.4 µM. This was confirmed experi-
mentally by assaying a 10× dilution of a solu-
tion saturated with CPT (in PBS at pH 7.4 and 
37°C). This solution gave a fluorescence reading 
with values very similar to undiluted release runs 
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Figure 3. Drug release from porous silicon–poly(l‑lactide) (spin‑coated) surfaces. (A) Release 
of CPT from spin-coated pSi–PLLA composite and (B) corresponding Higuchi plot of CPT release.
CPT: Camptothecin; Ox: Oxidized; PLLA: Poly(l-lactide); pSi: Porous silicon.
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at the release end point (~1.4 µM). The absence 
of photobleaching over the maximal release 
period of 5 days was confirmed via sampling a 
standard CPT solution under the same condi-
tions. The CPT fluorescence did not change over 
that time period. 
To gain an idea of the release properties of 
the generated materials, the drug release pro-
files were plotted against zero-order, first-order, 
Higuchi, Hixson–Crowell and Ritger–Peppas 
models and their R2 values were compared as is 
a common practice in the literature [62–68]. 
Cell culture, staining & imaging 
Human lens epithelial cells, SRA 01/04, were 
seeded in 24-well plates at a density of 1 × 105 
cells per well in DMEM containing 10% fetal 
bovine serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 0.29 mg/ml glutamine (com-
plete medium) and allowed to attach overnight 
at 37°C and 5% CO
2
 in air. pSi films and 
monoliths were then placed etched side down 
onto the cells after changing to fresh medium. 
pSi films were left on the cells for 48 h, while the 
monoliths were left for 5 days. After incubation, 
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Figure 4. Drug release from poly(l‑lactide) monoliths. (A) Release of CPT from PLLA only and 
pSi–PLLA monoliths and (B) corresponding Higuchi plots of CPT release.
CPT: Camptothecin; PBS: Phosphate-buffered saline; PLLA: Poly(l-lactide); pSi: Porous silicon.
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the pSi films or monoliths were removed and 
the number of cells was assayed using the 
CellTiter Aqueous One® assay (Promega, WI, 
USA) according to the manufacturer’s instruc-
tions. The cells were then stained as follows: 
SYTOX® Green Stain (Invitrogen, CA, USA) 
was diluted 1/5000 in complete medium. The 
medium was replaced with SYTOX staining 
solution and incubated at 37°C for 20 min after 
which time the solution was replaced by Cell 
Mask Orange (Invitrogen) diluted to 1/2000 
in complete medium and incubated for 3 min. 
Cells were then washed with PBS pH 7.4 and 
fixed for 10 min in 3.7% formalin in PBS. The 
cells were washed twice with PBS, incubated 
in 2 µM Hoechst 33342 (Sigma, MO, USA) 
in PBS for 5 min, followed by washing twice 
with PBS. All samples were stored in buffered 
glycerol.
Samples were imaged on an Olympus IX71 
inverted microscope. The cells were counted 
based on the number of Hoechst dye-stained 
nuclei present in each image. The number of 
cells found in the untreated wells was used 
as the 100% mark and all further cell counts 
were reported relative to this. Cells exposed to 
medium containing 500 nM CPT were ana-
lyzed simultaneously with the composite materi-
als. An analysis of variance test was performed 
on the cell count data to test for statistical dif-
ferences (given as p-values). The level of sig-
nificance was set at a = 0.05 (i.e., if p < 0.05, 
samples were determined to be statistically 
significantly). All data analysis was performed 
with PASW Statistics 18 software (SPSS Inc., 
IL, USA).
(3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay
After the required incubation time (48 h for films 
or 5 days for monoliths) the pSi film or mono-
lith was removed from the cell culture well and 
the medium was replaced (1 ml). Subsequently, 
100 µl of (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS; CellTiter One reagent, 
Promega) was added and the cells were incu-
bated at 37°C for 2 h, after which time 100 µl 
aliquots were removed and analyzed at 490 nm 
on a VERSAmax™ tunable microplate reader 
with Softmax Pro 4.8 software (Molecular 
Devices, CA, USA).
Results & discussion
 n pSi characterization
Gravimetric analysis of the pSi films, as outlined 
by Canhan [25], was used to determine the poros-
ity of the films and gave values of approximately 
82%. A similar porosity of 75% was obtained 
by effective medium calculations from inter-
ferometric reflectance spectroscopy measure-
ments. Cross-sectional analysis of the films by 
means of SEM analysis gave a film thickness of 
approximately 7 µm (Figure 5A) and topo graphical 
anal ysis by AFM revealed a pore diameter of 
8–12 nm (Figure 5B).
The etched pSi films used to produce pSi mic-
roparticles for preparation of pSi–PLLA mono-
liths had a porosity of 70 and 79% by gravimetry 
and effective medium calculations, respectively. 
SEM analysis of the micro particles showed an 
assortment of slab-like structures that varied in 
Figure 5. Scanning electron microscopy and atomic force microscopy characterization of 
porous silicon. (A) Scanning electron microscopy micrograph showing the thickness of the porous 
silicon films and (B) tapping mode atomic force microscopy image of a porous silicon film used for 
grafting and spin coating of poly(l-lactide).
Color figure can be found online at www.futuremedicine.com/doi/full/10.2217/nnm.11.176
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size with an average particle size of 85 ± 45 µm 
(Figure 6A). Close inspection of the particles via 
SEM revealed that some of the larger particles 
had a tendency to curl up slightly (Figure 6B) and 
a thickness of around 10 µm (Figure 6C). AFM 
imaging revealed a pore size range of 12–16 nm 
(Figure 6D). 
 n Characterization of composite 
materials
The composite materials prepared for this 
work were characterized via IR spectroscopy, 
AFM, SEM and contact angle measurements. 
Characterization of the pSi–PLLA (grafted) 
composites is also described in our earlier 
work [38].
Chemical analysis of the composite materials 
via IR spectroscopy confirmed the presence of a 
PLLA layer. Figure 7 shows typical transmission 
IR spectra of each of the composite materials. In 
order to collect IR data, the composite materials 
were produced on p+ type (resistivity 3–6 Wcm, 
<1–0–0>) pSi to allow for transmission IR to be 
performed. The spectra of ozone-pSi-Ox (Figure 7) 
showed a strong and broad peak centered at 
1045 cm-1 due to asymmetric stretching vibrations 
of Si–O-Si surface bridging groups [69]. Other 
than a weak and broad peak centered around 
3415 cm-1 attributed to the presence of surface 
silanol groups, the spectrum lacked other peaks 
of significance. After the grafting of PLLA from 
pSi-Ox (pSi-Ox–PLLA; grafted) (Figure 7), the 
IR spectra still showed the strong characteristic 
peak at 1045 cm-1 and a new peak at 1349 cm-1, 
which was attributed to the methyl-bending 
vibrations of the PLLA. The broad band cen-
tered at 3400 cm-1 increased in intensity and was 
attributed to the free hydroxyl groups from the 
polymer termini as well as surface silanol groups. 
The peak at 1444 cm-1 was assigned to the asym-
metric CH
3
 deformation mode and the dual 
peak at 2920 and 2965 cm-1 corresponds to C-H 
stretching vibrations of the PLLA. Perhaps most 
notable was the appearance of a conspicuous new 
peak occurring at 1725 cm-1 attributed to the 
C=O stretching mode of the PLLA, confirming 
the presence of a PLLA on the surface.
Similar IR spectra were obtained after PLLA 
grafting from pSi functionalized with HEAPS 
and PEGS [38]. The spectrum of PLLA spin-
coated on ozone-pSi-Ox also showed the same 
characteristic set of peaks as the grafted samples 
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Figure 6. Scanning electron microscopy and atomic force microscopy images of porous 
silicon microparticles. (A) Scanning electron microscopy images of representative porous silicon 
microparticles. (B) A single microparticle. (C) Edge view of a single microparticle showing the layer 
thickness and the porous nature of the particle and (D) tapping mode atomic force microscopy 
image of a porous silicon film used to make porous silicon microparticles before electropolishing. 
Color figure can be found online at www.futuremedicine.com/doi/full/10.2217/nnm.11.176
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but with a greater intensity than seen for the latter 
(pSi-Ox–PLLA; spin-coated) (Figure 7). The spec-
tra of bulk PLLA used to produce the monolith 
materials (bulk PLLA with 5% w/w PEG 6000; 
average molecular weight 6000–7500 g/mol) 
(Figure 7) featured similar spectral peaks as the 
pSi–PLLA (grafted) and pSi–PLLA (spin-
coated) composites, with the exception of the 
region from 1000–1300 cm-1 (highlighted box 
in Figure 7). The C-O-C stretching vibrations 
and the C-H rocking modes observed for bulk 
PLLA in that region are overshadowed by the 
Si-O peak in the composite materials [70]. 
The PLLA by-product formed in solu-
tion during the surface-initiated ring-opening 
polymerization reaction was analyzed via size 
exclusion chromatography and found to have a 
molecular weight of approximately 9434 g/mol 
with a polydispersity of 1.13. This poly dispersity 
value is indicative of a well-controlled polymer-
ization reaction [71,72]. The determined average 
molecular weight also fits well with estimates 
from our previous work, which used TGA to 
estimate the average molecular weight of the 
surface-bound polymer produced on the pSi film 
at approximately 10,000 g/mol [38].
In terms of surface morphology, our earlier 
AFM study of the pSi–PLLA (grafted) pSi films 
showed the presence of PLLA nanobrushes 
[38]. The presence of the PLLA layer after spin 
Figure 8. Scanning electron microscopy and atomic force microscopy characterization of 
spin‑coated composite materials. (A) Cross-sectional scanning electron microscopy micrograph of 
an oxidized porous silicon–poly(l-lactide; spin-coated) and (B) tapping mode atomic force microscopy 
image of oxidized porous silicon–poly(l-lactide; spin-coated).
Color figure can be found online at www.futuremedicine.com/doi/full/10.2217/nnm.11.176
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Figure 7. Comparison of infrared spectra of the poly(l‑lactide) composite materials.
Ox: Oxidized; PEG: Polyethylene glycol; PLLA: Poly(l-lactide); pSi: Porous silicon.
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coating and melting of the PLLA on pSi films 
was confirmed via SEM (Figure 8A). SEM revealed 
a 4.2-µm thick layer on top of the pSi and that 
3.6 µm of this PLLA layer had penetrated 
into the pSi pore structure. This left the lower 
3.0 µm of the pSi unfilled. The extent of pen-
etration could possibly be increased by longer 
melting times or by physically forcing the mol-
ten PLLA into the pores. On the other hand, 
the presence of a pore volume not filled with 
PLLA presents opportunities for high drug load-
ing. In this case, the PLLA would act as a plug, 
closing off the pores. Indeed, AFM analysis of 
the pSi–PLLA (spin-coated) (Figure 8B) shows 
that the pores have been totally occluded by 
polymer, in contrast to the pSi-Ox (Figure 5B) and 
to pSi–PLLA (grafted) [38]. Due to solubility 
issues, the molecular weight of PLLA used for 
the spin coating and monolith production was 
determined from TGA measurements by using 
the published relationship between decompo-
sition temperature and molecular weight [73]. 
We obtained a molecular weight of around 
25,000 g/mol.
Figure 9. Scanning electron microscopy analysis of degradation occurring in the  
poly(l‑lactide) monolith structures. Scanning electron microscopy micrographs of poly(l-lactide)–
camptothecin monolith surfaces (A) before degradation in phosphate-buffered saline and (B) after 
degradation for 1 month, and scanning electron microscopy micrographs of monolithic  
porous silicon–poly(l-lactide)–camptothecin composites (C) before degradation and (D & E) after 
1 month of degradation in phosphate-buffered saline.
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We also prepared monolithic materials by 
melt casting bulk polymerized PLLA with 
and without pSi microparticles in an alumi-
num mould. The PLLA monoliths without 
pSi microparticles were characterized by SEM 
(Figure 9A). They were an opaque white and their 
surface appeared quite smooth in the SEM 
image. The monolithic pSi–PLLA composites 
showed a similar topography by SEM (Figure 9C) 
although they appeared light brown in color. 
We investigated the stability of the monoliths 
in PBS under the same conditions used for the 
release experiments. After 1 month of shaking 
incubation at 37°C in nonsterile PBS (pH 7.4), 
washing with water and drying, the outer sur-
face of the monoliths had cracked extensively 
(Figures 9B, D & e). Macroscopically, the entire 
structure had become more opaque. This was 
observed both in the absence and presence of 
pSi microparticles. These results indicate that 
significant PLLA degradation has occurred in 
PBS over this time frame. We also found evi-
dence of degradation of the pSi microparticles, 
as the pSi–PLLA monoliths became lighter in 
color. In some cases, individual microparticles 
became exposed during the incubation in PBS 
(Figures 9D & e). Monolith materials kept in PBS 
solution for a period of 3 months lost all struc-
tural integrity (see TABle 1 for the estimated deg-
radation times of all three types of composite 
material). 
Surface wettability is an important parameter 
for biodegradable materials. We determined the 
WCA for all of the composite materials pro-
duced in this study (TABle 2), including the three 
different grafted composites. It should be noted 
that the WCA is influenced both by the sur-
face chemistry and the topography of the mate-
rial, and in some cases both parameters change 
between the composites.
Sessile drop WCA measurements qualita-
tively showed similar wettability for all the 
grafted composites. As shown in TABle 2, upon 
surface-initiated polymerization of PLLA, a 
WCA increase of approximately 40° (14–54°) 
was observed. Approximately 30° higher con-
tact angles were subsequently measured on 
pSi–PLLA (spin-coated). This difference in wet-
tability was possibly caused by the thin coating 
on the grafted composites still exposing some 
surface chemistry of the pSi or the difference in 
topography between the grafted and the spin-
coated surfaces (Figure 8B) [38]. The monolithic 
composite and bulk polymerized PLLA gave very 
similar WCA to the spin-coated composites.
 n CPT loading & release 
Each composite material was loaded with the 
cytotoxic drug CPT, a relatively water-insoluble 
small-molecule alkaloid drug [74] first isolated 
from the stem wood of Camptotheca acuminata 
by Wall et al. [75]. CPT is an antineoplastic agent 
that exerts its anti-tumor effect by the inhibi-
tion of the nuclear enzyme topo isomerase I 
[76]. Although CPT shows a broad spectrum of 
activity towards many cancers it has yet to be 
used in vivo due to its poor solubility and rapid 
hydrolysis to a ring-open carboxylate form with 
lower pharmacological activity [61]. As we are 
interested in drug delivery to the eye, CPT was 
selected as a model drug because of its rapid cyto-
toxic profile and the ease with which it can be 
quantified. It has a similar molecular mass to the 
DNA cross-linking agent mito mycin C, which 
is administered topically to the eye after some 
glaucoma-filtering surgery [77]. Mitomycin C is 
also cytotoxic for mammalian cells, but is more 
difficult to quantify accurately than CPT. 
Table 2. Water contact angle of porous silicon–poly(l‑lactide) 
composite materials and bulk polymerized poly(l‑lactide) (n = 6).
Material WCA ± standard deviation
pSi-Ox 14.0 ± 2.0
pSi-Ox–PLLA (grafted) 54.0 ± 5.4
pSi–HEAPS–PLLA (grafted) 54.1 ± 8.4
pSi–PEGS–PLLA (grafted) 49.4 ± 3.7
pSi–PLLA (spin-coated) 80.3 ± 2.6
pSi–PLLA (monolith) 78.2 ± 3.3
Bulk polymerized PLLA [91] 79.0 ± 3.0
HEAPS: N-(hydroxyethyl)-3-aminopropyl trimethoxysilane; Ox: Oxidized; 
PEGS: N-(triethoxysilylpropyl)-O-polyethylene oxide urethane; PLLA: Poly(l-lactide); pSi: Porous 
silicon; WCA: Water contact angle.
Table 1. Camptothecin loading of composite materials and their estimated 
degradation times.
Material type Loading (nmol of CPT per cm2) Degradation time
pSi–PLLA (grafted) 37.0 6.4 <24 h
pSi–PLLA (spin-coated) 178.7 ± 9.6 Weeks
pSi–PLLA monolith 11.5 ± 0.1 nmol/mg Months
CPT: Camptothecin; PLLA: Poly(l-lactide); pSi: Porous silicon.
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The loading was performed by placing the pSi 
films or microparticles into a solution of CPT 
in DMF before drying under vacuum, or in the 
case of the monoliths by solid–solid mixing, as 
described in the section ‘Production and load-
ing of pSi–PLLA monoliths’. The final loading 
values are displayed in TABle 1. Release experi-
ments with CPT were performed in PBS, hence 
we expected the CPT to remain in its bioactive 
(closed ring) form. The total CPT loadings for 
each of the surface-grafted materials was calcu-
lated from the average of the final fluorimetry 
reading of each release curve, while the loadings 
for the spin-coated and monolithic materials 
were calculated gravimetrically. These total load-
ing values (TABle 1) were then used to convert the 
released amounts of CPT (determined via fluo-
rimetry) into percentage of total CPT released. 
In the case of the films, the loaded amount was 
normalized to the film’s surface area, while load-
ing was normalized to total weight in the case 
of the monoliths. 
The release of CPT from all of the grafted 
pSi–PLLA composites (Figure 2A & TABle 3) showed 
a substantial burst release within the first 1 h 
before a transition release of approximately 5 h, 
in which the release rate slows and starts to 
plateau into a slow linear release phase, lasting 
approximately 10 h. This is due to the incom-
plete coating of the pores allowing the CPT 
to diffuse quickly from the pSi network, pos-
sibly also due to the high wettability of those 
materials. Release from the PLLA grafted com-
posites was only marginally slower than from 
unpolymerized, CPT-loaded pSi films (denoted 
pSi-Ox), which showed a fast burst release of 
51.9% of loaded CPT over the first 1 h. The 
pSi–PEGS–PLLA surface was able to release the 
largest percentage of CPT in a linear fashion 
(21.4% of the total CPT loading). The transi-
tion release, which is neither a burst release nor 
a linear release, was typically responsible for the 
release of approximately 30–50% of the total 
CPT loading (TABle 3). 
pSi is susceptible to hydrolytic degradation 
and the thin PLLA layer provides relatively little 
protection to the pSi scaffold [7,78]. Indeed, these 
grafted films completely dissolved within the 
15-h time frame of the release curves and, hence, 
released their full CPT payload (approximately 
37.0 nmol of CPT per cm2 of pSi on average for 
the four different composite materials). These 
materials are clearly unsuitable for long-term 
controlled drug release applications. However, 
they are adequate for short-term release, such as 
that required for the delivery of an antibiotic.
The release of CPT from the spin-coated 
pSi–PLLA composites (Figure 3 & TABle 3) into PBS 
showed a burst release of 0.7% of the loaded 
material at a rate of 5.1 nmol/cm2.h within 
the first 30 min before a linear release phase 
over approximately 38 h (8% of total loading, 
0.4 nmol/cm2.h). The release from these materi-
als did not show a pronounced transition phase 
as observed for the pSi–PLLA (grafted) com-
posites. These materials were not as susceptible 
to hydrolytic degradation over this time frame 
since the thicker PLLA layer protects the pSi 
scaffold. Indeed, it took several weeks before pSi 
degradation was visible. 
Considering the linear release rate, these 
materials could potentially release CPT for up 
to 400 h or roughly 6.5 days and, hence, possess 
attractive release properties. It is straight forward 
Table 3. Comparison of camptothecin release rates for the different types of composite materials and their 
corresponding R2 values.
Material Burst rate 
(nmol/cm2.h)
Burst 
release 
(%)
Linear rate 
(nmol/cm2.h)
Linear 
release 
(%)
Linearity 
(R2)
Transition 
release 
(%)
Final 
release 
(%)
Approximate 
100% release 
time
pSi-Ox† 21.6 51.9 0.7 16.6 0.970 31.6 100.0 15–20 h
pSi-Ox–PLLA (grafted)† 13.8 36.3 0.6 13.0 0.950 50.7 100.0 15–20 h
pSi–HEAPS–PLLA (grafted)† 13.4 48.2 0.4 12.2 0.982 39.7 100.0 15–20 h
pSi–PEGS–PLLA (grafted)† 14.7 36.0 1.0 21.4 0.983 42.5 100.0 15–20 h
pSi–PLLA (spin-coated)‡ 5.1 0.7 0.4 8.0 0.984 0.4 9.1 400 h
PLLA–CPT (monolith)§ 7.6 1.1 0.7 5.3 0.981 2.6 9.0 50 days
pSi–PLLA–CPT (monolith)§ 2.6 0.4 0.1 1.0 0.979 0.8 2.2 232 days
†Burst release calculated over the first 1 h, linear release and R2 values calculated from 6 h to release end.
‡Burst release calculated over the first 0.5 h, linear release and R2 values calculated from 1 to 38 h.
§Burst release calculated over the first 2 h, linear release and R2 values calculated from 20 to 120 h.
CPT: Camptothecin; HEAPS: N-(hydroxyethyl)-3-aminopropyl trimethoxysilane; Ox: Oxidized; PEGS: N-(triethoxysilylpropyl)-O-polyethylene oxide urethane; 
PLLA: Poly(l-lactide); pSi: Porous silicon.
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to generate pSi membranes spin-coated with 
PLLA, rather than films, to create fully bio-
degradable implantable drug release materials. 
Once the drug payload has been completely 
released, there are clear advantages to the 
composite material degrading in its entirety.
We next compared CPT release from mono-
liths with and without pSi microparticles 
(Figure 4 & TABle 3). We conjectured that the 
release of CPT from pSi microparticles embed-
ded within the PLLA structure would be slower 
than CPT release from PLLA directly, assum-
ing equivalent amounts of CPT are loaded. The 
PLLA-only monoliths were loaded with solid 
CPT dispersed in the PLLA melt (PLLA–CPT), 
while the pSi–PLLA–CPT monolith was gener-
ated by the addition of pSi microparticles pre-
viously loaded with CPT. The release curves 
for the first 2 days (Figure 4A) illustrate a burst 
release phase of 1.1 and 0.4% CPT release for 
the PLLA–CPT and pSi–PLLA–CPT mono-
liths, respectively, before reaching a prolonged 
linear release phase. Once this linear release 
phase was reached, the monoliths were taken 
out and washed before being placed back into 
release buffer and monitored (PBS recharge mark 
Figure 4A). Monolith materials demonstrated lin-
ear release for 5 days (Figure 4A). Only a small 
transition release was observed between the 
burst and linear release phases (TABle 3). Over the 
period of linear release, the CPT release rate from 
the PLLA–CPT monoliths (~0.7 nmol/cm2.h) 
was higher when compared with pSi–PLLA 
(spin-coated) (~0.4 nmol/cm2.h). However, the 
pSi–PLLA–CPT monoliths gave a linear release 
rate of only 0.2 nmol/cm2.h). The difference 
between the two monoliths may be the result of 
the CPT being trapped into the pore network of 
the pSi particles, which are, in turn, encapsulated 
within the PLLA monolith.
Given that both monoliths had approximately 
the same maximum loading of 878.4 nmol of 
CPT per monolith and the total release per-
centage of CPT from the PLLA–CPT and 
pSi–PLLA–CPT monoliths (over 5 days) was 
9.0 and 2.2%, respectively, we can conclude that 
the preloading of CPT into the pSi before mono-
lith production resulted in a substantially slower 
release profile. Extrapolating the release data over 
longer release periods, PLLA–CPT composites 
should theoretically be able to release CPT for 
50 days, while the pSi–PLLA–CPT monolith 
could release for over 200 days, four-times longer. 
It is important to note that PLLA is susceptible 
to hydrolytic degradation and, as we have shown 
by SEM, this effect will alter the structure of the 
monoliths over several weeks, which in turn may 
affect the release rate at extended time periods. It 
is interesting to note that the pSi microparticles 
were still intact inside the PLLA monoliths even 
after 1 month of incubation at 37°C as the SEM 
images in Figures 9D & e show. While the pH of the 
bulk solution remained at pH 7.4, it is possible 
that the local pH in the monolith was acidic due 
to the degrading PLLA, which would stabilize 
the pSi microparticles.
When comparing the release of drugs from 
these materials to a release model, a range of 
physical characteristics need to be taken into 
consideration. These include water diffusion 
into the matrix, drug diffusion out of the matrix, 
polymer swelling, polymer dissolution, pSi dis-
solution, porosity and changing matrix dimen-
sions. We have fitted the release data to the com-
mon release models applicable to our materials 
(TABle 4) [79–84].
The data shown in TABle 4 reveal that the zero-
order and Hixson–Crowell models were not suit-
able models for this set of release data. The latter 
model describes the drug release by dissolution 
and changes in surface area and diameter of the 
particles or tablets [82]. For the grafted thin films, 
the best fit was in fact the first-order model, which 
revealed quite high R2 values (above 0.948). The 
Table 4. Comparison of R2 values of fitting camptothecin release to different release models.
Material Zero order First order Higuchi Hixson–Crowell Ritger–Peppas n
pSi-Ox 0.643 0.952 0.861 0.334 – –
pSi-Ox–PLLA (grafted) 0.672 0.975 0.886 0.383 – –
pSi–HEAPS–PLLA (grafted) 0.624 0.948 0.853 0.340 – –
pSi–PEGS–PLLA (grafted) 0.776 0.954 0.950 0.429 0.982 0.44
pSi–PLLA (spin-coated) 0.973 0.977 0.994 0.704 0.998 0.58
PLLA–CPT (monolith) 0.962 0.966 0.995 0.754 0.996 0.53
pSi–PLLA–CPT (monolith) 0.901 0.903 0.988 0.627 0.993 0.44
–: Model could not be fitted to data as the release was too fast; CPT: Camptothecin; HEAPS: N-(hydroxyethyl)-3-aminopropyl trimethoxysilane; Ox: Oxidized; 
PEGS: N-(triethoxysilylpropyl)-O-polyethylene oxide urethane; PLLA: Poly(l-lactide); pSi: Porous silicon.
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Higuchi plot fits the release from the pSi–PLLA 
(grafted) samples reasonably well and also gives 
very good fits for the monoliths and for pSi–PLLA 
(spin-coated). The Higuchi model is an empiri-
cal model commonly used to describe the release 
kinetics of drugs from insoluble porous materials 
[80,81]. It is well established and commonly used 
for modeling drug release from matrix systems 
[81,85,86]. The model is based on a square root of 
a time-dependent process of Fickian diffusion.
Q k tt H 1 2=
In this model, the plot of percentage drug 
released (Qt) versus the square root of time 
should be linear for a purely diffusion controlled 
process with the slope of the plot equal to the 
Higuchi release rate constant k
H
 [87]. Deviations 
from linearity indicate that the release is not 
purely diffusion controlled, and may be influ-
enced by other factors, such as the degradation 
of the matrix material. 
All of the grafted pSi–PLLA composites 
showed a two-phase release in the Higuchi plot 
and there are quite clearly two different release 
rates before and after 4 h (Figure 2B). This was 
attributed to the degradation of the these mate-
rials over the time course of the release and, 
hence, the process was no longer only diffusion 
controlled as the composite dissolution will 
assist the release of CPT [87]. The Higuchi plot 
of CPT release from the spin-coated compos-
ite material was linear (R2 = 0.994) confirm-
ing the diffusion-based release in these more 
stable composite materials. Drug release from 
the monolithic materials was mainly diffusion 
controlled over the time frame of 5 days based 
on the Higuchi plots (Figure 4B) (R2 = 0.995 for 
the PLLA-only monolith and R2 = 0.988 for the 
pSi–PLLA monolith). 
The Ritger–Peppas model also f it the 
data well. This model (also known as 
Korsmeyer–Peppas) is used to fit drug release 
from polymeric thin f ilms, cylinders and 
spheres [88]. This model can be applied to any 
system to gain an idea of the apparent overall 
release phenomenon regardless of the specific 
mechanisms of release actually occurring [88]. 
The Ritger–Peppas model is limited to the 
first 60% of a drug release curve only; diffu-
sion must be 1D (aspect ratio is at least 10:1) 
and the drug diffusion coefficient must be 
concentration independent. These conditions 
are met for most composites in this study. For 
the grafted samples, with the exception of 
pSi–PEGS–PLLA, the release data could not 
be fitted to this model since release was too 
fast to allow for more then two data points to 
be plotted below the 60% release limit. The 
Ritger–Peppas equation is shown below [83,84].
M
M K tm
n
=t
where M
t
 is the amount of drug released at time 
(t), M is the total amount of drug in dosage 
form, K
m
 is the kinetic constant and n is the 
release exponent. The n exponent is estimated 
from the slope of log
(Mt/M)
 versus log
time
. Values 
of n < 0.5 indicate Fickian diffusion (case 1) 
and values of 0.5 < n < 1.0 indicate non-Fickian 
(anomalous) diffusion [83,84,89]. When using the 
Ritger–Peppas equation n < 0.5 is only possible 
when porous systems are involved. In these cases, 
the release mechanism is a combination of dif-
fusion through the swollen matrix polymer and 
diffusion through the water-filled pores of the 
porous material [89].
The n-values from the Ritger–Peppas model 
differ for the composite materials used here. 
pSi–PLLA (spin-coated) shows an n-value of 
0.58 (TABle 4), indicating that this material is 
being released via a combination of Fickian 
and non-Fickian diffusion. The same is seen 
for the PLLA–CPT monolith. However, with 
pSi–PLLA monoliths, the release seems to be 
by Fickian diffusion. This indicates that the 
release can be controlled from these composite 
materials by simply varying the formulation of 
the composite materials.
 n Cell cytotoxicity 
The CPT released from the pSi–PLLA com-
posite materials was expected to show cytotoxic 
effects on human lens epithelial cells (SRA cell 
line), a relevant cell line for in vitro testing of 
drug release to the anterior segment of the eye.
Fluorescence microscopy ana lysis of the SRA 
cells in Figure 10 revealed that untreated cells 
appeared densely packed after the incubation 
period (Figure 10A), while exposure to 500 nM 
CPT (positive control) significantly reduced the 
number of cells remaining adherent (Figure 10B). 
The CPT concentration used in the positive con-
trol (500 nM) is approximately 71.5% of the 
IC
50
 value of 700 nM found by Peel et al. [90]. 
These images also reveal that the CPT-exposed 
cells were notably larger than their untreated 
counterparts, a trend that was also observed for 
the CPT-loaded composites (Figures 10C–e), which 
showed very few cells with larger cytoplasms 
and multiple nuclei, clear signs of CPT-induced 
DNA damage.
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First, counts of cells adherent to tissue culture 
plates were performed after 48-h incubation of 
SRA cells in contact with the grafted and spin-
coated composite materials, and after 5 days for 
the monoliths. The extended incubation with the 
monoliths was justified by taking into account 
the substantially slower drug release rate from 
this material. Cell counts in the sample wells 
were normalized to cell counts from a standard 
untreated culture with all cells seeded at the same 
density (Figure 10). Cells in contact with 500 nM 
CPT solution (48 h and 5 days for films and 
monoliths, respectively) were also counted. Sink 
conditions were not maintained for cell culture 
experiments, as increasing the cell culture volume 
above 2 ml in each well of a 24-well plate results 
in an insufficient surface area:volume ratio to 
maintain appropriate levels of oxygenation in the 
medium. TABle 5 shows the estimated concentra-
tion of CPT in the cell culture medium based 
on the release curves in Figures 2–4. These are not 
measured values and are only indicative of the 
possible concentration in each cell culture well.
We also performed the colorimetric MTS assay 
using a CellTiter One assay kit (Promega), which 
quantifies the activity of cellular enzymes that 
reduce MTS to a formazan dye, giving a purple 
color. The absorbance can then be related to cell 
viability. The cell viability after exposure to all 
composite materials was assayed in this man-
ner and the results from the MTS assay were in 
close agreement with the cell counts (Figure 11). 
The 100% control used for the MTS assay was 
untreated cells grown under the same conditions 
as those exposed to the CPT-containing materials.
The positive control (500 nM CPT in cell 
culture medium) effectively induced cell death 
in the SRA cells and reduced the percentage of 
cells to approximately 60.6%. The cell count 
results for the film-based composites (Figure 11) 
showed that all the CPT-loaded materials caused 
a significant reduction in the SRA cell numbers 
when compared with untreated cells (p ≤ 0.007), 
a similar reduction was seen for the positive con-
trol. This result confirms that the released CPT 
is still in a bioactive form. CPT-loaded pSi-Ox 
(pSi-Ox–CPT) showed the greatest reduction 
in cell numbers, with only 43.5% of cells viable 
after incubation compared with the negative con-
trol. From the release curves, the estimated CPT 
concentration in culture medium after 2 days for 
the CPT-loaded pSi-Ox and pSi–PLLA (grafted) 
Figure 10. Fluorescence microscopy images of SRA cells stained with SYTOX® Green, Cell Mask™ Orange and 
Hoechst® 33342 after incubation on camptothecin‑loaded composite materials. (A) Untreated (2 days), (B) 500 nM 
camptothecin in complete medium (2 days), (C) grafted porous silicon–poly(l-lactide) (2 days), (D) spin-coated porous silicon–poly(l-
lactide) (2 days) and (E) monolith materials (5 days). All images were taken with 10× magnification.
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films averaged 2.78 µM (TABle 5). The spin-coated 
sample also showed the least reduction with 
68.1% of cells compared with the untreated nega-
tive control. The estimated CPT concentration 
in culture medium after 2 days was 0.95 µM, 
consistent with the expected slower release com-
pared with the grafted samples. When an analysis 
of variance test was performed on the cell death 
found with the grafted pSi–PLLA and spin-coated 
composite materials, no statistically significant 
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Figure 11. Cell counts, expressed as a percentage of the number of live cells in the average untreated well, for the 
film (taken after 2 days of incubation) and monolith (taken after 5 days of incubation) based materials.
abs: Absorbance; CPT: Camptothecin; HEAPS: N-(hydroxyethyl)-3-aminopropyl trimethoxysilane; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Ox: Oxidized; PEGS: N-(triethoxysilylpropyl)-O-polyethylene oxide urethane; 
PLLA: Poly(l-lactide); pSi: Porous silicon.
Table 5. Estimated camptothecin release amounts and corresponding cell viability.
Sample Average estimated CPT 
concentration in media (µM)
Cell count 
viability (%)
MTS cell 
viability (%)
500 nM std (2 days) 0.50 60.6 ± 6.5 63.2 ± 2.3
pSi-Ox only 0.00 97.8 ± 5.1 99.1 ± 2.6
pSi-Ox–CPT 2.78 43.5 ± 10.6 50.8 ± 15.4
pSi–PLLA–CPT (grafted) 2.78 52.5 ± 5.5 59.7 ± 4.4
pSi–PLLA (spin-coated) 0.95 68.1 ± 6.9 70.7 ± 12.3
500 nM std (5 days) 0.50 22.1 ± 3.1 36.3 ± 2.9
PLLA only 0.00 83.6 ± 7.3 83.9 ± 7.4
PLLA–CPT (5 days) 17.54 0.9 ± 0.4 4.2 ± 1.9
pSi–PLLA–CPT (5 days) 4.20 1.3 ± 0.3 0.0 ± 1.8
CPT: Camptothecin; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; 
Ox: Oxidized; PLLA: Poly(l-lactide); pSi: Porous silicon; std: Standard.
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difference was found. Cell numbers in contact 
with the non-CPT-loaded pSi-Ox material were 
essentially unchanged from the controls (97.8%), 
illustrating that the pSi component of the com-
posite material has only minimally toxic effects 
on the cells.
The CPT-loaded monoliths (Figure 11) appeared 
to induce the most effective cell death with less 
than 5% of cells remaining viable when compared 
with the negative control after 5 days. The esti-
mated CPT concentration in culture medium for 
PLLA–CPT after 5 days was 17.54 µM, while for 
pSi–PLLA–CPT monoliths, the estimated CPT 
concentration in culture medium was 4.20 µM. 
The positive control (500 nm CPT in cell culture 
medium) showed significantly less cellular toxic-
ity due to the much lower concentration of CPT 
in solution (TABle 5). The PLLA monolith with-
out loaded CPT showed a slightly reduced cell 
count (83.6%) compared with the negative con-
trol (p < 0.001). However, there was significantly 
greater cell toxicity with the two CPT-containing 
monoliths (p < 0.001). It is also possible that the 
presence of the composite materials not loaded 
with CPT may have caused reduced nutrient flow 
to the cells by covering the cells during the incu-
bation period and possibly due to some toxicity 
from the residual Sn(Oct)
2
 catalyst.
Conclusion
In this article, we described the fabrication of 
three different architectures of PLLA and nano-
structured pSi. These composites are biodegrad-
able and inorganic/organic hybrids. The com-
bination of a pliable polymeric material with a 
highly porous material, both of which are biode-
gradable, should be advantageous for applications 
in localized drug delivery, such as in the treat-
ment of ocular diseases, where flexibility (e.g., for 
ease of implantation) and high drug payload are 
desirable attributes. We demonstrated the loading 
and release of cytotoxic topoisomerase inhibitor 
CPT, a model cytotoxic drug of a similar size 
to 5-fluorouracil and mitomycin C, commonly 
used in glaucoma surgery. The morphology of 
the composite materials greatly affected the drug 
release behavior. pSi surfaces grafted with thin 
films of PLLA by surface-initiated polymerization 
possessed similar release behavior to pSi lacking 
the PLLA grafting (pSi-Ox) and were deemed to 
only be effective for release periods of less than 
24 h. These materials also gave rise to a substan-
tial burst release. pSi–PLLA (spin-coated) showed 
slower CPT release and should sustain release 
over more than 1 week. The release properties of 
the spin-coated composites are tunable by varying 
the thickness and infiltration depth of the PLLA 
film into the pSi film. This will be the focus of a 
future study. Monoliths with CPT loaded into pSi 
microparticles (pSi–PLLA–CPT) showed slower 
CPT release in comparison with monoliths where 
CPT was simply mixed directly into the polymer 
(PLLA–CPT). Monolithic structures are suitable 
for drug release over time frames of more than 
1 month. Our proof-of-principle in vitro experi-
ments with human lens epithelial cells suggest 
that the pSi–PLLA composites may be suitable for 
localized drug therapy for blinding conditions of 
the human eye such as uveitis, glaucoma and cor-
neal neovascularization. The loading and release 
of immunosuppressants and antiglaucoma drugs 
will be the subject of a future study.
Future perspective
The Si–polymer hybrid materials described here 
have demonstrated potential for the controlled 
delivery of small molecular drugs. In the near 
future, improvements in surface modification 
with smart polymers could allow for site-specific 
targeting and improved composite materials that 
are capable of better protecting therapeutic agents 
in vivo while also improving the release properties. 
We envision the future use of fully biodegradable 
Si–polymer composite implants that have tailored 
release characteristics. For example, the develop-
ment of Si–polymer hybrid materials could lead 
to the development of environ mentally respon-
sive, pulsatile drug release systems that are able to 
sense the need for a drug and release the required 
amount of a therapeutic molecule accordingly.
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